Genetic Engineering News | Aerie Raises $30M to Progress Glaucoma Drug into Phase III Genetic Engineering News Osage University Partners and existing investors Alta Partners and TPG Biotech also participated. Aeri plans to use the new funds to continue development of its glaucoma portfolio, and in particular progress lead candidate AR-12286 into Phase III ... Duke spinoff Aerie raises $30M to test glaucoma drug Aerie Pharma banks $30M round for Ph3 glaucoma drug study Aerie Pharmaceuticals Completes $30 Million Series B Financing to Fund Further ... |
Monday, March 7, 2011
Aerie Raises $30M to Progress Glaucoma Drug into Phase III - Genetic Engineering News
http://acrowdedfire.com/fatalheartbreak.html
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment